Effect of tamoxifen on linear growth of precocious female SD rats

Huamei MA, Yanhong LI, Minlian Du, Qiuli CHEN, Hongshan CHEN.
Department of Pediatrics, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China

INTRODUCTION
Tamoxifen is a selective estrogen receptor modulator, which is administrated in girls with peripheral precocious puberty such as McCune-Albright syndrome.

AIM
To explore the effect of tamoxifen on the linear growth of precocious pubertal female rats.

METHOD
At 16-22 day of age, 16 precocious pubertal female rats (induced by 300 μg danazol s.c. at 5-day old), were randomized blocks (brood) to 2 groups (n=8). Group TAM received once weekly 20mg/kg tamoxifen s.c for 5 times, while Group Ctrl received solvent injections. Rats were killed 5 weeks later. Measurements of body weight and length (nose-anus length) were taken every 3-4 days. Vaginal opening was observed from 4-week age. On the day of sacrifice, body weight, body length and left tibial length were measured, plasma were taken for determining E2 level, IGF-1 (IRMA) and IGFBP-3 (IRMA) concentrations; liver samples were taken for detecting GHRmRNA, IGF-1mRNA or IGFBP-3mRNA, and does not alter local IGF-1 and IGF-1R level on growth plate.

RESULTS
1. Skeletal growth: Tamoxifen decreases both of the body weight and body length without influencing the tibial length.
2. Growth plate HE measurement: Tamoxifen increases the width of PZ[(185.0 ± 12.7μm) VS (172.5 ± 61.0μm), P<0.05], decrease the width of HZ[(167.5 ± 37.0μm) VS (188.3 ± 33.7μm), P<0.05] and cell number[(7.2 ± 1.0) VS (8.9 ± 0.6), P<0.05] in HZ without changing total EGP width [358.1 ± 45.0 VS (373.3 ± 35.7 μm), P<0.05].
3. Plasma concentration determination: Tamoxifen does not alter plasma E2 level, decreases plasma IGFBP-3 level (443.8 ± 65.5 ng/ml versus 537.7 ± 94.1 ng/ml, P<0.05).

CONCLUSIONS
Tamoxifen inhibited growth, especially weight gain and fat accumulation. Besides, tamoxifen has dual effects of anti-estrogen and estrogen-like on the growth plate. So tamoxifen is inapplicable for central precocious puberty treatment. The safety of tamoxifen for peripheral precocious puberty needs to be reevaluated.

REFERENCES

ACKNOWLEDGEMENTS

CONTACT INFORMATION
Email huameima@163.com